ADAP News and Press, Adaptimmune Therapeutics plc From 08/21/20

Volatility watch: Heading into the new week, short interest is on the rise on Royal Bank of Canada (NYSE: RY ) ahead of the bank's earnings report on August 26 and AstraZeneca (NYSE: AZN ) amid COVID-19 developments. Meanwhile, GameStop (NYSE: GME ) is cruising along with an exceedi...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

The following companies have filed for mixed shelf offerings: More news on: Calithera Biosciences, Inc., Adaptimmune Therapeutics plc, PTC Therapeutics, Inc., Healthcare stocks news, , Read more ...

Adaptimmune Therapeutics plc (ADAP) Q2 2020 Earnings Conference Call August 6, 2020, 8:00 AM ET Company Participants Juli Miller - Senior Director, IR Adrian Rawcliffe - CEO Elliot Norry - Senior VP and Chief Medical Officer Helen Tayton-Martin - Co-Founder and Chief Business O...

Image source: The Motley Fool. Adaptimmune Therapeutics PLC   (NASDAQ: ADAP) Q2 2020 Earnings Call Aug 6, 2020 , 8:00 a.m. ET Operator Continue reading

Adaptimmune (NASDAQ: ADAP ) : Q2 GAAP EPS of -$0.04 beats by $0.20 . More news on: Adaptimmune Therapeutics plc, Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...

- Reported responses in multiple solid tumor types during ASCO with updates at upcoming congresses in Q4 - - Continued progress toward launch of ADP-A2M4 for sarcoma in the US in 2022 with ongoing enrollment of patients in SPEARHEAD-1 - - Granted access to PRIority MEdicines (PRIME) re...

The European Medicines Agency (EMA) grants PRIME status to Adaptimmune Therapeutics' (NASDAQ: ADAP ) lead candidate ADP-A2M4, a SPEAR T-cell therapy, for the treatment of synovial sarcoma , a cancer of soft tissue such as muscle or ligaments. It also has Orphan Drug and Regenerative Med...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 23, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the European Medicines Agency (EMA) has granted access to the PRIME initiative to the Company for ADP-A2M4 for...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for Q2 2020, before the U.S. markets open on Thursday, August 6, ...